8,054 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Wick Capital Partners LLC

Wick Capital Partners LLC purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,054 shares of the company’s stock, valued at approximately $1,142,000.

A number of other institutional investors and hedge funds also recently modified their holdings of NBIX. Invesco Ltd. grew its holdings in Neurocrine Biosciences by 6.1% in the fourth quarter. Invesco Ltd. now owns 343,421 shares of the company’s stock valued at $48,707,000 after purchasing an additional 19,810 shares during the period. Corient Private Wealth LLC raised its stake in Neurocrine Biosciences by 82.1% during the fourth quarter. Corient Private Wealth LLC now owns 7,292 shares of the company’s stock worth $1,034,000 after purchasing an additional 3,287 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in Neurocrine Biosciences by 29.6% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 40,957 shares of the company’s stock worth $5,809,000 after purchasing an additional 9,355 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of Neurocrine Biosciences in the 4th quarter valued at $418,000. Finally, NewEdge Advisors LLC boosted its holdings in shares of Neurocrine Biosciences by 5.5% in the 4th quarter. NewEdge Advisors LLC now owns 12,998 shares of the company’s stock valued at $1,844,000 after purchasing an additional 672 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several research reports. Guggenheim restated a “buy” rating and set a $175.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price on the stock. HC Wainwright boosted their price target on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Finally, Sanford C. Bernstein began coverage on Neurocrine Biosciences in a research note on Friday, May 22nd. They set an “outperform” rating and a $221.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $187.52.

Insider Activity

In other Neurocrine Biosciences news, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $160.25, for a total value of $1,762,750.00. Following the transaction, the insider directly owned 25,846 shares of the company’s stock, valued at $4,141,821.50. This trade represents a 29.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 2,261 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $156.71, for a total value of $354,321.31. Following the transaction, the insider owned 16,225 shares in the company, valued at approximately $2,542,619.75. This represents a 12.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 355,234 shares of company stock worth $55,330,060 in the last quarter. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Down 0.4%

Neurocrine Biosciences stock opened at $158.29 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $169.57. The firm has a fifty day moving average of $148.02 and a 200-day moving average of $140.72. The firm has a market capitalization of $15.92 billion, a P/E ratio of 24.39, a PEG ratio of 1.19 and a beta of 0.40.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.